This website requires certain cookies to work and uses other cookies to help you have the best experience. By visiting this website, certain cookies have already been set, which you may delete and block. By closing this message or continuing to use our site, you agree to the use of cookies. Visit our updated privacy and cookie policy to learn more.
This Website Uses Cookies By closing this message or continuing to use our site, you agree to our cookie policy. Learn MoreThis website requires certain cookies to work and uses other cookies to help you have the best experience. By visiting this website, certain cookies have already been set, which you may delete and block. By closing this message or continuing to use our site, you agree to the use of cookies. Visit our updated privacy and cookie policy to learn more.
On March 17, 2023, two bipartisan pieces of legislation were introduced to the U.S. House of Representatives with the goal of requiring the U.S. Food and Drug Administration (FDA) to regulate cannabidiol (CBD) products in foods and dietary supplements.
The U.S. Senate has introduced a bill that would enforce stricter regulation of the Generally Recognized as Safe (GRAS) rule and that calls for the creation of a new office within the U.S. Food and Drug Administration that would assess chemicals in food.